Literature DB >> 10891538

Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma.

A Handa1, T Tokunaga, T Tsuchida, Y H Lee, H Kijima, H Yamazaki, Y Ueyama, H Fukuda, M Nakamura.   

Abstract

Osteosarcoma is a malignant bone tumor characterized by hypervascularity. Neuropilins (NRPs), which is expressed by human tumor cells, is known to be a potent receptor for vascular endothelial growth factor (VEGF). We examined NRPs mRNA expression in 30 osteosarcomas. The osteosarcomas with NRP2 expression (n=24) showed a significantly increased vascularity (P<0.0014, Mann-Whitney U test). Osteosarcomas with NRP2 showed significantly poorer prognosis than those without NRP2 (P=0.016, Wilcoxon's test). These results suggest that NRP acts as a VEGF-amplifier in a paracrine or autocrine manner in the osteosarcoma. NRP2 expression cooperatively promotes angiogenesis and growth in osteosarcomas with VEGF expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891538     DOI: 10.3892/ijo.17.2.291

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  36 in total

1.  Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.

Authors:  Gang Han; Yan Wang; Wenzhi Bi; Jinpeng Jia; Wei Wang; Meng Xu
Journal:  Clin Exp Med       Date:  2015-08-29       Impact factor: 3.984

Review 2.  The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review.

Authors:  Jin-Tao Qu; Mei Wang; Hai-Long He; Yu Tang; Xiao-Jian Ye
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-25       Impact factor: 4.553

Review 3.  Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.

Authors:  Patrick J Messerschmitt; Ashley N Rettew; Robert E Brookover; Ryan M Garcia; Patrick J Getty; Edward M Greenfield
Journal:  Clin Orthop Relat Res       Date:  2008-07-08       Impact factor: 4.176

Review 4.  Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions.

Authors:  Prasanta K Hota; Matthias Buck
Journal:  Cell Mol Life Sci       Date:  2012-06-29       Impact factor: 9.261

Review 5.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

6.  Prognostic value and in vitro biological relevance of Neuropilin 1 and Neuropilin 2 in osteosarcoma.

Authors:  Aleksandar Boro; Matthias Je Arlt; Harald Lengnick; Bernhard Robl; Maren Husmann; Josefine Bertz; Walter Born; Bruno Fuchs
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

7.  Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis.

Authors:  L Mariani; C Beaudry; W S McDonough; D B Hoelzinger; T Demuth; K R Ross; T Berens; S W Coons; G Watts; J M Trent; J S Wei; A Giese; M E Berens
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

8.  Comment on Xu XW et al.: Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.

Authors:  Shaozhong He; Zhenyu Xiao; Longhua Chen; Shizhong Xiong
Journal:  Tumour Biol       Date:  2014-05-23

9.  Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling.

Authors:  Wessen Maruwge; Pádraig D'Arcy; Annika Folin; Slavica Brnjic; Johan Wejde; Anthony Davis; Fredrik Erlandsson; Jonas Bergh; Bertha Brodin
Journal:  Onco Targets Ther       Date:  2008-11-01       Impact factor: 4.147

10.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.